Mobile

A phase IA/II, multi-center, open-label study of HCD122 administered intravenously once weekly for four weeks in adult patients with advanced non-Hodgkin's or Hodgkin's lymphoma who have progressed af...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-004888-22

A phase IA/II, multi-center, open-label study of HCD122 administered intravenously once weekly for four weeks in adult patients with advanced non-Hodgkin's or Hodgkin's lymphoma who have progressed after at leastr two prior therapies

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Dose escalation phase Primary objective: 1.To determine the maximum tolerated dose (MTD) or the recommended Phase II dose of HCD122 when administered as a single agent intravenously (IV) once weekly for 4 weeks to adult patients with advanced non-Hodgkin’s or Hodgkin’s lymphoma who have progressed after at least two prior therapies Dose expansion phase Primary objective: 1.To assess clinical response at the MTD or the recommended phase II dose in adult patients with advanced non-Hodgkin’s or Hodgkin’s lymphoma who have progressed after at least two prior therapies

Critère d'inclusion

  • Advanced non Hodgkin's or Hodgkin's lymphoma

Liens